<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047031</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0280</org_study_id>
    <nct_id>NCT03047031</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an active surveillance study to monitor the real world safety of nintedanib in Indian
      patients with Idiopathic Pulmonary Fibrosis. The safety of nintedanib has been assessed in
      clinical trials.This active surveillance aims to collect the safety data of 200 IPF patients
      treated with nintedanib in approved indication after the commercial availability of the drug
      in India (23rd January 2017). The objective is to look at safety of nintedanib in the real
      world setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all Adverse Drug Reactions (ADRs) in nintedanib treated patients</measure>
    <time_frame>up to 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all serious adverse events (SAEs) in nintedanib treated patients</measure>
    <time_frame>up to 56 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who require dose reductions, interruptions and discontinuation due to adverse events</measure>
    <time_frame>up to 56 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients who started treatment with nintedanib after 23rd January, 2017 and have permanently discontinued the drug (as decided by the investigator) at the time of participation in the active surveillance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients who started treatment with nintedanib after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>Patients who have been newly prescribed nintedanib at the time of participation in the active surveillance</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This active surveillance will include all IPF patients treated with nintedanib per the
        inclusion/exclusion criteria at selected centres during the first two years after the
        commercial availability of the drug.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with documented diagnosis of Idiopathic Pulmonary Fibrosis (IPF) based upon
             ATS/ERS/JRS/ALAT 2011 guidelines (nintedanib na√Øve or pirfenidone pre-treated) who
             have initiated or will initiate nintedanib according to the package insert after the
             commercial availability of drug in India (23rd January 2017).

          -  Patients in whom it is possible to obtain voluntary informed consent either from the
             patient or patient's legally authorised representative (applicable for Group B and C
             patients).

          -  Patients in whom data collection is possible from the medical records (applicable for
             Group A and B patients)

          -  Further inclusion criteria apply

        Exclusion Criteria:

          -  Patients who were previously treated with nintedanib.

          -  Patients who have initiated or will initiate nintedanib concomitantly with
             pirfenidone..

          -  Patients who are participating in a clinical trial.

          -  Further exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Johns medical College and Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priya Ramachandra</last_name>
      <phone>9663590386</phone>
      <email>supriarvind@yahoo.co.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gleneagles Global Hospital</name>
      <address>
        <city>Chennai</city>
        <zip>600100</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijil Rahulan</last_name>
      <phone>+91-044-44777000</phone>
      <email>vkrahulan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Artemis Health Institute</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Himanshu Garg</last_name>
      <phone>91 9717156157</phone>
      <email>himanshu.garg@medanta.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Allergy Asthma Bronchitis Institute, Kolkata</name>
      <address>
        <city>Kolkatta</city>
        <zip>700017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alok Gopal Ghoshal</last_name>
      <phone>91-9830068023</phone>
      <email>agghosal@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King George Medical University</name>
      <address>
        <city>Lucknow</city>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surya Kant</last_name>
      <phone>+91-5222255167</phone>
      <email>skantpulmed@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midland Healthcare and Research Centre</name>
      <address>
        <city>Lucknow</city>
        <zip>226006</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhanu Singh</last_name>
      <phone>0522-2333333</phone>
      <email>bps2159@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P.D. Hinduja National Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zarir Udwadia</last_name>
      <phone>22-24447353</phone>
      <email>zfu@hindujahospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

